Jasper Therapeutics Inc

NASDAQ:JSPR   3:56:29 PM EDT
0.80
-0.08 (-8.80%)
Products

Jasper Announces FDA Fast Track Designation For JSP191

Published: 09/15/2022 12:39 GMT
Jasper Therapeutics Inc (JSPR) - Jasper Therapeutics Announces FDA Fast Track Designation for Jsp191, a Novel Monoclonal Antibody Targeting Cd117, in the Treatment of Patients With Severe Combined Immunodeficiency (scid) Undergoing Allogeneic Hematopoietic Stem Cell Transplant.
Jasper Therapeutics Inc - on Track to Initiate a New Study of Jsp191 As a Therapeutic in Second-line Therapy for Patients With Lower-risk Mds Later This Year.